Page last updated: 2024-12-08

5,6-didehydrosparteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-dehydrosparteine: urinary metabolite of sparteine; RN given refers to (7S-(7alpha,14alpha,14abeta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5,6-didehydrosparteine : A quinolizidine alkaloid obtained by formal dehydrogenation at the 5,6-position of sparteine. It is a metabolite of sparteine found in human urine and plasma. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID160614
CHEBI ID143195
SCHEMBL ID11352489
MeSH IDM0130372

Synonyms (11)

Synonym
5-dehydrosparteine
5,6-didehydrosparteine
CHEBI:143195
2130-67-8
(7s,14s,14as)-1,3,4,7,9,10,11,13,14,14a-decahydro-2h,6h-7,14-methanodipyrido[1,2-a:1',2'-e][1,5]diazocine
5,6-ddhsp
7,14-methano-2h,6h-dipyrido(1,2-a:1',2'-e)(1,5)diazocine, 1,3,4,7,9,10,11,13,14,14a-decahydro-, (7s-(7alpha,14alpha,14abeta))-
SCHEMBL11352489
5,6-dehydrospartein
DTXSID20943804
(1s,9s,10s)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadec-2-ene

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" and the pharmacokinetic parameters were estimated."( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.
Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
"To establish the bioavailability of tropisetron (5 mg) administered orally as capsule compared with 2 mg given intravenously."( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.
Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001
)
0.31
"Tropisetron exhibits a wide range of oral bioavailability at therapeutic doses, which is mainly determined by CYP2D6 activity."( Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.
Bucher, M; Färber, L; Grobecker, H; Kees, F; Mair, G; Mörike, K, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Of the 141 subjects dosed with debrisoquin, 10 proved to be poor oxidizers, and of the 143 subjects dosed with phenformin, 11 were poor oxidizers."( Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.
Eichelbaum, M; Idle, JR; Oates, NS; Smith, RL; Woolhouse, NM, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
quinolizidine alkaloid
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
organic heterotetracyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (63.64)18.7374
1990's3 (27.27)18.2507
2000's1 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.51 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]